Literature DB >> 30991396

Prognosis of Primary Osteosarcoma in Elderly Patients: A Comparison between Young and Elderly Patients.

Hiroyuki Tsuchie1, Makoto Emori2, Hiroyuki Nagasawa3, Naohisa Miyakoshi3, Yasutaka Murahashi2, Junya Shimizu2, Emi Mizushima2, Toshihiko Yamashita2, Yoichi Shimada3.   

Abstract

OBJECTIVES: Osteosarcoma is the most common malignant bone tumor in childhood. Although a poorer prognosis has been described in older patients, few reports have focused solely on primary osteosarcoma. We evaluated the clinical features of elderly patients with primary osteosarcoma.
MATERIALS AND METHODS: Ninety-four patients were included in this retrospective study, and we divided them into 2 groups (older patients and younger patients) based on a cut-off age of 40 years. The patients' information, including age, tumor type, location, presence of metastasis, American Joint Committee on Cancer (AJCC) stage, treatment-related factors, local and distant relapse, and outcome, was collected. We compared the clinical courses between the 2 groups in all and only deceased patients.
RESULTS: In all patients, the frequency of chemotherapy in the older group was significantly lower than in the younger group (p < 0.001), and tumors were more frequent in axial bone in the older patients (p = 0.041). Only in patients with surgical treatment, histological effectiveness after chemotherapy in the older group was lower than in the younger group (p = 0.041). The older patients showed a poorer prognosis (p = 0.031). However, the 5-year overall survival rate in the older patients was more favorable than that in the younger patients only among deceased patients (p =0.032). Only the existence of metastasis affected the prognosis in older patients (p = 0.012).
CONCLUSION: Primary osteosarcoma in elderly patients showed a high incidence of axial bone involvement, a low rate of chemotherapy, and resistance to chemotherapy. Although the final life prognosis is poor, survival may be relatively prolonged.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Elderly; Osteosarcoma; Primary; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 30991396      PMCID: PMC6771043          DOI: 10.1159/000500404

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  20 in total

1.  Osteosarcoma in patients older than 65 years.

Authors:  Alessandra Longhi; Costantino Errani; Daniel Gonzales-Arabio; Cristina Ferrari; Mario Mercuri
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

2.  Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma.

Authors:  T Naka; T Fukuda; N Shinohara; Y Iwamoto; Y Sugioka; M Tsuneyoshi
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

3.  Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.

Authors:  Yukihide Iwamoto; Kazuhiro Tanaka; Kazuo Isu; Akira Kawai; Shin-ichiro Tatezaki; Takeshi Ishii; Kazuyoshi Kushida; Yasuo Beppu; Masamichi Usui; Akio Tateishi; Kiyoo Furuse; Takeshi Minamizaki; Noriyoshi Kawaguchi; Shinya Yamawaki
Journal:  J Orthop Sci       Date:  2009-08-07       Impact factor: 1.601

4.  Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.

Authors:  Thomas Colding-Rasmussen; Andrea Pohly Thorn; Peter Horstmann; Catherine Rechnitzer; Lisa Lyngsie Hjalgrim; Anders Krarup-Hansen; Michael Mørk Petersen
Journal:  Acta Oncol       Date:  2017-07-25       Impact factor: 4.089

5.  Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan.

Authors:  Kyoji Okada; Tadashi Hasegawa; Jun Nishida; Akira Ogose; Takahiro Tajino; Toshihisa Osanai; Michiro Yanagisawa; Masahito Hatori
Journal:  Ann Surg Oncol       Date:  2004-11       Impact factor: 5.344

6.  A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor.

Authors:  T Wada; K Isu; N Takeda; M Usui; S Ishii; S Yamawaki
Journal:  Oncology       Date:  1996 May-Jun       Impact factor: 2.935

7.  Primary osteosarcoma in patients older than 40 years of age.

Authors:  Dae Geun Jeon; Soo Yong Lee; Wan Hyung Cho; Won Seok Song; Jong Hoon Park
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

8.  Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy.

Authors:  G Rosen; R C Marcove; A G Huvos; B I Caparros; J M Lane; A Nirenberg; A Cacavio; S Groshen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  Osteosarcoma over the age of forty.

Authors:  R J Grimer; S R Cannon; A M Taminiau; S Bielack; B Kempf-Bielack; R Windhager; M Dominkus; G Saeter; H Bauer; I Meller; M Szendroi; G Folleras; M San-Julian; J van der Eijken
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

10.  Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases.

Authors:  Shintaro Iwata; Takeshi Ishii; Akira Kawai; Toru Hiruma; Tsukasa Yonemoto; Hiroto Kamoda; Naofumi Asano; Masanobu Takeyama
Journal:  Ann Surg Oncol       Date:  2013-08-23       Impact factor: 5.344

View more
  5 in total

1.  Development and Validation of Prognostic Nomograms for Elderly Patients with Osteosarcoma.

Authors:  Xiaoqiang Liu; Shaoya He; Xi Yao; Tianyang Hu
Journal:  Int J Gen Med       Date:  2021-09-14

2.  Risk and Prognostic Factors for Different Organ Metastasis in Primary Osteosarcoma: A Large Population-Based Analysis.

Authors:  Guijun Xu; Haixiao Wu; Yanting Zhang; Yao Xu; Xu Guo; Vladimir P Baklaushev; Vladimir P Chekhonin; Karl Peltzer; Jun Wang; Feng Lu; Guowen Wang; Xin Wang; Wenjuan Ma; Chao Zhang
Journal:  Orthop Surg       Date:  2022-03-16       Impact factor: 2.071

3.  Successful Treatment of Vertebral Osteosarcoma in a Cat Using Marginal Surgical Excision and Chemotherapy.

Authors:  Antonio Giuliano; Virginie De Busscher; Diane D A Lu; Karen W L Ng; Julia A Beatty
Journal:  Vet Sci       Date:  2022-06-23

4.  Outcomes of comprehensive treatment for primary osteosarcoma.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Naohiro Oka; Masao Akagi
Journal:  SAGE Open Med       Date:  2020-05-20

5.  Overexpression of KIAA1199, a novel strong hyaluronidase, is a poor prognostic factor in patients with osteosarcoma.

Authors:  Kan Ito; Yoshihiro Nishida; Kunihiro Ikuta; Hiroshi Urakawa; Hiroshi Koike; Tomohisa Sakai; Jiarui Zhang; Yoshie Shimoyama; Shiro Imagama
Journal:  J Orthop Surg Res       Date:  2021-07-07       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.